Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer.
J Thorac Oncol., Dec;2(12):1112-6 (2007)
The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.
J Thorac Oncol., Jan;3(1):68-74 (2008)
Late esophageal toxicity after radiation therapy for head and neck cancer.
Head Neck., Feb;32(2):178-83 (2010)
Clinical-dosimetric analysis of measures of dysphagia including gastrostomy-tube dependence among head and neck cancer patients treated definitively by intensity-modulated radiotherapy with concurrent chemotherapy.
Radiat Oncol., 4:52 (2009)
Evaluating the role of prophylactic gastrostomy tube placement prior to definitive chemoradiotherapy for head and neck cancer.
Int. J. Radiat. Oncol. Biol. Phys., Nov;78(4):1026-32 (2010)
Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial.
Clin Lung Cancer., Jan;12(1):33-7 (2011)
Feasibility study of intra-patient sorafenib dose-escalation or re-escalation in patients with previously treated advanced solid tumors.
Invest New Drugs., Oct;30(5):2001-7 (2012)
Concurrent chemoradiation strategies in the management of unresectable stage III non-small-cell lung cancer.
Clin Lung Cancer., May;3 Suppl 2:S42-8 (2002)
Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial.
Clin Lung Cancer., Jan;5(4):231-6 (2004)
Treatment of extensive small cell lung cancer.
Hematol. Oncol. Clin. North Am., Apr;18(2):373-85 (2004)
Gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II California cancer consortium trial.
Clin Lung Cancer., Sep;6(2):102-7 (2004)
An evaluation of barriers to accrual in the era of legislation requiring insurance coverage of cancer clinical trial costs in California.
Cancer J., 10(5):294-300 (2004)
Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: a phase I California Cancer Consortium Trial.
Anticancer Drugs., Mar;16(3):317-21 (2005)
Identification of novel targeting peptides for human ovarian cancer cells using "one-bead one-compound" combinatorial libraries.
Mol. Cancer Ther., May;4(5):806-13 (2005)
Thrombotic thrombocytopenic purpura associated with quetiapine.
Ann Pharmacother., 39(7-8):1346-8 (2005)
Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategies.
Clin Lung Cancer., Feb;8 Suppl 2:S61-7 (2007)
Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial.
J Thorac Oncol., Feb;1(2):126-34 (2006)
Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I study.
Invest New Drugs., Aug;25(4):351-5 (2007)
Concurrent carboplatin, etoposide and thoracic radiation for poor-risk stage III non-small-cell lung carcinoma: a pilot study.
Int. J. Radiat. Oncol. Biol. Phys., Apr;38(1):157-61 (1997)
Chemoradiotherapy for poor-risk stage III non-small cell lung cancer.
Semin. Oncol., Aug;24(4 Suppl 12):S12-110-S12-112 (1997)